The Spectrum of Papillophlebitis

• Published in: Ocular immunology and inflammation 2024-12, Vol.32 (10), p.2515-2520
• Main Authors: Abdel Jalil, Sara, Amer, Radgonde
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Angiogenesis Inhibitors - therapeutic use; Female; Fluorescein Angiography; Follow-Up Studies; Glucocorticoids - therapeutic use; Humans; Intravitreal Injections; Male; Optic Disk - pathology; Retinal Vein Occlusion - diagnosis; Retinal Vein Occlusion - drug therapy; Retinal Vein Occlusion - etiology; Retrospective Studies; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A - antagonists & inhibitors; Visual Acuity - physiology; Young Adult
• ISSN: 0927-3948; 1744-5078; 1744-5078
• DOI: 10.1080/09273948.2024.2359622

Papillophlebitis is a rare condition, manifesting as CRVO in the young adults. We aim to present our experience in managing patients with papillophlebitis. Retrospective review of patients' medical files. Included were seven patients with a mean presenting age of 24.86 ± 4.4 years and mean follow-up of 40.4 ± 50.5 months. No pre-existing systemic illness was reported by any patient. One patient was subsequently diagnosed to have Behçet disease and another patient was diagnosed with homozygous mutation to MTHFR C6771. On presentation, fluorescein angiograms showed diffuse vascular and optic disc leakage. Four patients presented with papillophlebitis-associated CME, for which they were treated with systemic steroids and intravitreal anti-VEGF injections. One patient showed full recovery. In 3 patients, due to the protracted course of papillophlebitis and refractory CME, adalimumab was added. All 3 patients eventually showed complete resolution of CME. Two of them eventually developed extensive peripheral capillary non-perfusion that was treated with panretinal photocoagulation. Three patients did not develop CME: In two patients, papillophlebitis resolved after a short course of prednisone while in the third patient, papillophlebitis resolved spontaneously. Mean ± SD presenting log MAR VA was 0.2 ± 0.32 and it was 0.057 ± 0.11 at the last follow-up. To the best of our knowledge, this is the first description that suggests a role for TNF-ɑ blockers in the management of patients with recalcitrant papillophlebitis and non-responsive CME. Further studies are needed in order to thoroughly investigate the molecular background of papillophlebitis and clinical outcomes associated with this class of medications.